Hematopoietic Stem Cell Transplantation
We focus on clinical aspects of acute myeloid leukemia (AML) in adults. Patients with AML are diagnosed, including extensive genetic analyses with constitutional control DNA and biobanking, and treated according to research and routine protocols at Skåne University Hospital, Lund, with careful monitoring and follow-up.
Lab work includes genetics in collaboration with Fioretos group, high-sensitive detection of measurable residual disease and genetic subclones during follow-up in collaboration with Ehinger and Saal groups. Patient AML cells are studied in vitro and in mouse models, including sensitivity to substance libraries in collaboration with Magnusson group.
Data on all Swedish AML patients diagnosed since 1997 are registered in the Swedish AML registry in national collaboration within the Swedish AML group and Regional Cancer Center South, Lund, and data on management and outcome according to clinical and genetic parameters are continuously assessed.
Genetic and functional characterization of human AML cell clones and subclones, with clinical annotation to assess biological – clinical associations.
Population-based evaluation of management and outcome of AML in Sweden with international collaboration
Swedish AML registry has world recognition due to high coverage, quality of data including management and follow-up, and potential to analyse data on patients not entering clinical trials. Collaboration with Genomics Medicine Sweden will provide population-based analyses on clinical impact of genetic characteristics in AML.
(name linked to profile in Lund University research portal)
Principal Investigator, Gunnar [dot] Juliusson [at] med [dot] lu [dot] se
Researcher, Aurelie [dot] Baudet [at] med [dot] lu [dot] se
Associate Professor, Chairman of the Swedish AML-group, Vladimir [dot] Lazarevic [at] med [dot] lu [dot] se